<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fomepizole: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fomepizole: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Fomepizole: Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="8633" href="/d/html/8633.html" rel="external">see "Fomepizole: Drug information"</a> and <a class="drug drug_patient" data-topicid="15553" href="/d/html/15553.html" rel="external">see "Fomepizole: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52866968"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Antizol</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1058824"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antidote, Ethylene Glycol Toxicity</span>;</li>
<li>
<span class="list-set-name">Antidote, Methanol Toxicity</span></li></ul></div>
<div class="block dop drugH1Div" id="F173911"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Fomepizole therapy should begin immediately upon suspicion of ethylene glycol or methanol ingestion. Consultation with a clinical toxicologist or poison control center is highly recommended to determine if fomepizole therapy is indicated.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc2b07d2-927f-4d3f-a56b-0e1117998423">Ethylene glycol or methanol toxicity; patient not requiring hemodialysis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ethylene glycol or methanol toxicity; patient not requiring hemodialysis: </b>Limited data available; consider consultation with a clinical toxicology or poison control center:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: Initial: 15 mg/kg loading dose; followed by 10 mg/kg every 12 hours for 4 doses; then 15 mg/kg every 12 hours until ethylene glycol or methanol concentrations have been reduced to &lt;20 mg/dL and patient is asymptomatic with normal pH (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11099610','lexi-content-ref-11192468','lexi-content-ref-11134452','lexi-content-ref-11581485','lexi-content-ref-15578220','lexi-content-ref-15329167','lexi-content-ref-Fisher.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11099610','lexi-content-ref-11192468','lexi-content-ref-11134452','lexi-content-ref-11581485','lexi-content-ref-15578220','lexi-content-ref-15329167','lexi-content-ref-Fisher.1'])">Ref</a></span>). <b>Note:</b> For severe toxicity requiring concomitant hemodialysis, see "Dosing: Altered Kidney Function: Pediatric."</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51110549"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents (limited data available) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20586570']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20586570'])">Ref</a></span>): <b>Note:</b> Hemodialysis should be considered as an adjunct to fomepizole in patients with renal failure, significant or worsening metabolic acidosis, or ethylene glycol or methanol concentrations ≥50 mg/dL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25493973']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25493973'])">Ref</a></span>). The following dosage adjustments should be used for any patient receiving hemodialysis regardless of renal function.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prior to the start of hemodialysis:</i> To determine if the patient requires a dose of fomepizole at the start of hemodialysis, determine when the last dose was administered.</p>
<p style="text-indent:-2em;margin-left:6em;">If &lt;6 hours since last fomepizole dose: Do <b>not</b> administer dose upon beginning dialysis.</p>
<p style="text-indent:-2em;margin-left:6em;">If ≥6 hours since last fomepizole dose: Administer next scheduled dose upon beginning dialysis.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>During hemodialysis</i>: Administer every 4 hours. Alternatively, a loading dose of 10 to 20 mg/kg followed by a continuous infusion 1 to 1.5 mg/kg/hour during hemodialysis has been described in case reports (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8699550']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8699550'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Upon completion of hemodialysis; dependent upon the time between the last dose and the end of hemodialysis:</i> To determine if the patient requires a dose of fomepizole at the time of completion of hemodialysis, determine when the last dose was administered.</p>
<p style="text-indent:-2em;margin-left:6em;">If &lt;1 hour since last fomepizole dose: Do <b>not</b> administer a dose at the end of hemodialysis.</p>
<p style="text-indent:-2em;margin-left:6em;">If 1 to 3 hours since last fomepizole dose: Administer <sup>1</sup>/<sub>2</sub> of the next scheduled dose at the end of hemodialysis.</p>
<p style="text-indent:-2em;margin-left:6em;">If &gt;3 hours since last fomepizole dose: Administer the next scheduled dose at the end of hemodialysis.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maintenance dose off hemodialysis</i>: Administer every 12 hours starting from the time last dose administered.</p></div>
<div class="block dohp drugH1Div" id="F51110550"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Fomepizole is metabolized in the liver. Specific dosage adjustments have not been determined in patients with hepatic impairment.</p></div>
<div class="block doa drugH1Div" id="F173901"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8633" href="/d/html/8633.html" rel="external">see "Fomepizole: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e8f3299c-f941-4b64-ab90-550c872c196f">Acetaminophen overdose, adjunctive agent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acetaminophen overdose, adjunctive agent:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Consultation with a clinical toxicologist or poison control center is highly recommended to determine if fomepizole therapy is indicated; routine use is not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34785186']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34785186'])">Ref</a></span>). Dosing is based on use in ethylene glycol and methanol toxicity, as well as preclinical data in healthy volunteers who received supratherapeutic doses of acetaminophen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31768936']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31768936'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>Limited data available: 15 mg/kg, followed by 10 mg/kg every 12 hours as needed. A single loading dose is often described in case reports; however, additional doses may be reasonable based on patient presentation and severity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34336301','lexi-content-ref-30956824','lexi-content-ref-34709101','lexi-content-ref-Rampon.1','lexi-content-ref-31785979','lexi-content-ref-32538692','lexi-content-ref-31785980']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34336301','lexi-content-ref-30956824','lexi-content-ref-34709101','lexi-content-ref-Rampon.1','lexi-content-ref-31785979','lexi-content-ref-32538692','lexi-content-ref-31785980'])">Ref</a></span>). The duration of therapy should be determined in consultation with a clinical toxicologist or poison control center (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34785186']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34785186'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="81045758-e458-401e-843a-94532966c43b">Ethylene glycol or methanol toxicity</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ethylene glycol or methanol toxicity:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Fomepizole therapy should begin immediately upon suspicion of ethylene glycol or methanol ingestion. Consultation with a clinical toxicologist or poison control center is highly recommended to determine if fomepizole therapy is indicated.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 15 mg/kg (loading dose), followed by doses of 10 mg/kg every 12 hours for 4 doses, then 15 mg/kg every 12 hours until ethylene glycol or methanol concentrations have been reduced to &lt;20 mg/dL and patient is asymptomatic with normal pH. <b>Note:</b> For severe toxicity requiring concomitant hemodialysis, see dosage adjustment in altered kidney function.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990493"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Hemodialysis should be considered as an adjunct to fomepizole in patients with kidney failure, significant or worsening metabolic acidosis, or ethylene glycol or methanol concentrations ≥50 mg/dL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10080845','lexi-content-ref-25493973']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10080845','lexi-content-ref-25493973'])">Ref</a></span>). The following dosing adjustments should be used for any patient receiving hemodialysis regardless of kidney function.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Prior to the start of hemodialysis: </b></p>
<p style="text-indent:-2em;margin-left:4em;">To determine if the patient requires a dose of fomepizole at the start of hemodialysis, determine when the last dose was administered.</p>
<p style="text-indent:-2em;margin-left:4em;">If the last dose of fomepizole was given &lt;6 hours ago, do not administer another dose upon beginning hemodialysis.</p>
<p style="text-indent:-2em;margin-left:4em;">If the last dose of fomepizole was given ≥6 hours ago, administer next scheduled dose upon beginning hemodialysis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>During hemodialysis: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Intermittent hemodialysis:</i> During intermittent hemodialysis, administer fomepizole every 4 hours. Alternatively, a continuous IV infusion of 1 mg/kg/hour may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26551875']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26551875'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CRRT:</i> During CRRT, administer fomepizole every 8 hours. Alternatively, a continuous IV infusion of 0.5 mg/kg/hour may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34585641','lexi-content-ref-26551875']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34585641','lexi-content-ref-26551875'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Upon completion of hemodialysis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">To determine if the patient requires a dose of fomepizole at the time of completion of hemodialysis, determine when the last dose was administered.</p>
<p style="text-indent:-2em;margin-left:4em;">If the last dose of fomepizole was given &lt;1 hour ago, do not administer a dose at the end of hemodialysis.</p>
<p style="text-indent:-2em;margin-left:4em;">If the last dose of fomepizole was given 1 to 3 hours ago, administer one-half of the next scheduled dose at the end of hemodialysis.</p>
<p style="text-indent:-2em;margin-left:4em;">If the last dose of fomepizole was given &gt;3 hours ago, administer the next scheduled dose at the end of hemodialysis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Maintenance dose when off hemodialysis:</b> Administer fomepizole every 12 hours (starting 12 hours from last dose administered).</p></div>
<div class="block doha drugH1Div" id="F50987779"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Fomepizole is metabolized in the liver. Specific dosage adjustments have not been determined in patients with hepatic impairment.</p></div>
<div class="block adr drugH1Div" id="F173870"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10% (≤3% unless otherwise noted):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia, facial flushing, hypotension, phlebitis, shock, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Dizziness (6%), drowsiness (6%), metallic taste (≤6%), agitation, altered sense of smell, anxiety, seizure, speech disturbance, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Unpleasant taste (≤6%), abdominal pain, decreased appetite, diarrhea, heartburn, hiccups, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Anuria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, disseminated intravascular coagulation (DIC), eosinophilia, lymphangitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased liver enzymes</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application site reaction, inflammation at injection site, pain at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Nystagmus, transient blurred vision, visual disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pharyngitis</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever, multi-organ failure</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing and/or case reports: Hypersensitivity reaction (mild; mild rash, eosinophilia)</p></div>
<div class="block coi drugH1Div" id="F173883"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to fomepizole, other pyrazoles, or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F173867"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; metabolized in the liver.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; fomepizole and its metabolites are excreted in the urine. Hemodialysis should be considered as an adjunct to fomepizole in patients with renal failure, significant acidosis (pH &lt;7.25 to 7.3), worsening metabolic acidosis, or ethylene glycol or methanol concentrations ≥50 mg/dL.</p>
<p style="text-indent:-2em;margin-left:4em;">• Isopropanol (isopropyl alcohol) poisoning: Fomepizole should <b>not</b> be administered in known isopropanol ingestions as the toxicity of isopropanol is predominantly due to the parent alcohol; inhibiting the metabolism of isopropanol may result in prolonged CNS depression, hypotension, or respiratory depression (Bekka 2001; Kraut 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: Should not be given undiluted or by bolus injection. Avoid using polycarbonate syringes or polycarbonate-containing needles (including polycarbonate filter needles) during dilution or administration; fomepizole may interfere with the integrity of polycarbonate products.</p></div>
<div class="block foc drugH1Div" id="F173877"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1.5 g/1.5 mL (1.5 mL)</p></div>
<div class="block geq drugH1Div" id="F173863"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323159"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Antizol Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g/mL (per mL): $1,233.20</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866969"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Antizol: 1 g/mL (1.5 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 g/mL (1.5 mL)</p></div>
<div class="block admp drugH1Div" id="F52612882"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV: Infuse as a diluted solution over 30 minutes; rapid infusion at a concentration of 25 mg/mL has been associated with vein irritation and phlebosclerosis. Avoid using polycarbonate syringes or polycarbonate-containing needles (including polycarbonate filter needles) during administration.</p></div>
<div class="block adm drugH1Div" id="F173880"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> All doses should be administered as a slow IV infusion (IVPB) over 30 minutes. Avoid using polycarbonate syringes or polycarbonate-containing needles (including polycarbonate filter needles) during administration.</p></div>
<div class="block sts drugH1Div" id="F173895"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Store at controlled room temperature, 20°C to 25°C (68°F to 77°F); fomepizole solidifies at temperatures &lt;25°C (77°F). If solution becomes solid in the vial, it should be carefully warmed by running the vial under warm water or by holding in the hand. Solidification does not affect the efficacy, safety, or stability of the drug. Diluted solution should be used within 24 hours and may be stored at room temperature or under refrigeration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Pharmacy supply of emergency antidotes:</i> Guidelines suggest that at least 1.5 to 4.5 g of fomepizole be stocked. Suggested amount is stated to be a sufficient quantity to treat 1 patient weighing 100 kg for an initial 8- to 24-hour period (Dart 2018); actual amount to be stocked should take into account site-specific and population-specific needs.</p></div>
<div class="block usep drugH1Div" id="F53566991"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Treatment of known or suspected methanol or ethylene glycol (antifreeze) poisoning alone or in combination with hemodialysis (FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Fomepizole is the preferred antidote for known or suspected ethylene glycol poisoning or methanol poisoning. If fomepizole is unavailable or if the patient is intolerant to fomepizole, ethanol therapy may be considered. Ethanol as an antidote is effective in the management of methanol and ethylene glycol poisoning (Thanacoody 2016; Zakharov 2015); however, ethanol is associated with a higher incidence of adverse events and medication errors (Bestic 2009; Lepik 2009; Lepik 2011).</p></div>
<div class="block mst drugH1Div" id="F7914140"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Fomepizole may be confused with omeprazole</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299362"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6220494"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F173886"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted. In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey, 2003).</p></div>
<div class="block mopp drugH1Div" id="F53566988"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Vital signs, arterial blood gases, acid-base status, renal function (BUN, creatinine, and urinalysis), liver function, WBC counts, anion and osmolar gaps, clinical signs and symptoms of toxicity (arrhythmias, seizures, coma); urinary oxalate, serum and urinary ethylene glycol or serum methanol level depending upon the agent ingested; formic acid level (methanol ingestion).</p></div>
<div class="block rerp drugH1Div" id="F53566746"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Ethylene glycol or methanol serum concentration: Goal: &lt;20 mg/dL (ethylene glycol SI: &lt;3.2 mmol/L; methanol SI: &lt;6.2 mmol/L).</p>
<p style="text-indent:-2em;margin-left:2em;">Therapeutic plasma fomepizole level: 0.8 mg/L (SI: 10 micromole/L).</p></div>
<div class="block pha drugH1Div" id="F173866"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Fomepizole competitively inhibits alcohol dehydrogenase, an enzyme which catalyzes the metabolism of ethanol, ethylene glycol, and methanol to their toxic metabolites. Ethylene glycol is metabolized to glycoaldehyde, then oxidized to glycolate, glyoxylate, and oxalate. Glycolate and oxalate are responsible for metabolic acidosis and renal damage. Methanol is metabolized to formaldehyde, then oxidized to formic acid. Formic acid is responsible for metabolic acidosis and visual disturbances.</p>
<p style="text-indent:-2em;margin-left:2em;">When used as adjunctive treatment for acetaminophen overdose, fomepizole is theorized to be protective during the injury phase as well as promote hepatocyte regeneration (Akakpo 2021; Akakpo 2022; Kang 2020). Fomepizole, via CYP2E1 inhibition, may attenuate the formation of N-acetyl-p-benzoquinone imine (NAPQI), a reactive metabolite of acetaminophen that contributes to hepatocellular injury (Akakpo 2018; Kang 2020). In addition, fomepizole may inhibit c-Jun N-terminal kinase, thereby preventing amplification of mitochondrial damage by limiting mitochondrial oxidant stress and hepatocellular death after NAPQI has already been generated (Akakpo 2018; Akakpo 2019).</p></div>
<div class="block phk drugH1Div" id="F173882"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of effect: Peak effect: Maximum: 1.5 to 2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Readily absorbed.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 0.6 to 1.02 L/kg; rapidly into total body water.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Negligible.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic to 4-carboxypyrazole (80% to 85% of dose), 4-hydroxymethylpyrazole, and their N-glucuronide conjugates; following multiple doses, induces its own metabolism via CYP oxidases after 30 to 40 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Varies with dose and duration. After 96 hours of administration, the self-induction of fomepizole metabolism results in a shortened half-life of 1.5 to 2 hours (McMartin 2012).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (1% to 3.5% as unchanged drug and metabolites).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038622"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Antizol</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Fomepizole serb</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Fomepizole eusa pharma</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Fomepizole eusa pharma | Fomepizole serb</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Fomepizole opi</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Antizol</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Fomepizole eusa pharma | Fomepizole opi/france</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Antizol | Fomepizole eusa pharma</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Fomepizole eusa pharma</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Fomepizole serb</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Antizol</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Antizol</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Fomepizole eusa pharma</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Fomepizole eusa pharma | Fomepizole serb</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Fomeject</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-34978586">
<a name="34978586"></a>Akakpo JY, Ramachandran A, Curry SC, Rumack BH, Jaeschke H. Comparing N-acetylcysteine and 4-methylpyrazole as antidotes for acetaminophen overdose. <i>Arch Toxicol</i>. 2022;96(2):453-465. doi:10.1007/s00204-021-03211-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/34978586/pubmed" id="34978586" target="_blank">34978586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34420083">
<a name="34420083"></a>Akakpo JY, Jaeschke MW, Ramachandran A, Curry SC, Rumack BH, Jaeschke H. Delayed administration of N-acetylcysteine blunts recovery after an acetaminophen overdose unlike 4-methylpyrazole. <i>Arch Toxicol</i>. 2021;95(10):3377-3391. doi:10.1007/s00204-021-03142-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/34420083/pubmed" id="34420083" target="_blank">34420083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30903181">
<a name="30903181"></a>Akakpo JY, Ramachandran A, Duan L, et al. Delayed treatment with 4-methylpyrazole protects against acetaminophen hepatotoxicity in mice by inhibition of c-Jun N-terminal kinase. <i>Toxicol Sci</i>. 2019;170(1):57-68. doi:10.1093/toxsci/kfz077<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/30903181/pubmed" id="30903181" target="_blank">30903181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29739258">
<a name="29739258"></a>Akakpo JY, Ramachandran A, Kandel SE, et al. 4-methylpyrazole protects against acetaminophen hepatotoxicity in mice and in primary human hepatocytes. <i>Hum Exp Toxicol</i>. 2018;37(12):1310-1322. doi:10.1177/0960327118774902<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/29739258/pubmed" id="29739258" target="_blank">29739258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33157119">
<a name="33157119"></a>Akakpo JY, Ramachandran A, Orhan H, Curry SC, Rumack BH, Jaeschke H. 4-methylpyrazole protects against acetaminophen-induced acute kidney injury. <i>Toxicol Appl Pharmacol</i>. 2020;409:115317. doi:10.1016/j.taap.2020.115317<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/33157119/pubmed" id="33157119" target="_blank">33157119</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Antizol.1">
<a name="Antizol.1"></a>Antizol (fomepizole injection) [prescribing information]. Dover, DE: Paladin Labs (USA) Inc; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Antizol.2">
<a name="Antizol.2"></a>Antizol (fomepizole) [product monograph]. St-Laurent, Quebec, Canada: Paladin Labs Inc; October 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12769509">
<a name="12769509"></a>Bailey B. Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women? <i>Birth Defects Res A Clin Mol Teratol</i>. 2003;67(2):133-140.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/12769509/pubmed" id="12769509" target="_blank">12769509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12216995">
<a name="12216995"></a>Barceloux DG, Bond GR, Krenzelok EP, et al. American Academy of Clinical Toxicology Practice Guidelines on the Treatment of Methanol Poisoning. <i>J Toxicol Clin Toxicol</i>. 2002;40(4):415-446.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/12216995/pubmed" id="12216995" target="_blank">12216995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10497633">
<a name="10497633"></a>Barceloux DG, Krenzelok EP, Olson K, et al. American Academy of Clinical Toxicology Practice Guidelines on the Treatment of Ethylene Glycol Poisoning. Ad Hoc Committee. <i>J Toxicol Clin Toxicol</i>. 1999;37(5):537-560.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/10497633/pubmed" id="10497633" target="_blank">10497633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12022913">
<a name="12022913"></a>Battistella M. Fomepizole as an Antidote for Ethylene Glycol Poisoning. <i>Ann Pharmacother</i>. 2002;36(6):1085-1089.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/12022913/pubmed" id="12022913" target="_blank">12022913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11099610">
<a name="11099610"></a>Baum CR, Langman CB, Oker EE, et al. Fomepizole Treatment of Ethylene Glycol Poisoning in an Infant. <i>Pediatrics</i>. 2000;106(6):1489-1491.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/11099610/pubmed" id="11099610" target="_blank">11099610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bekka.1">
<a name="Bekka.1"></a>Bekka R, Borron SW, Astier A, Sandouk P, Bismuth C, Baud FJ. Treatment of methanol and isopropanol poisoning with intravenous fomepizole. <i>J Toxicol Clin Toxicol</i>. 2001;39(1):59-67.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11192468">
<a name="11192468"></a>Benitez JG, Swanson-Biearman B, Krenzelok EP. Nystagmus Secondary to Fomepizole Administration in a Pediatric Patient. <i>J Toxicol Clin Toxicol</i>. 2000;38(7):795-798.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/11192468/pubmed" id="11192468" target="_blank">11192468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19004845">
<a name="19004845"></a>Bestic M, Blackford M, Reed M. Fomepizole: a critical assessment of current dosing recommendations. <i>J Clin Pharmacol</i>. 2009;49(2):130-137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/19004845/pubmed" id="19004845" target="_blank">19004845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Borron.1">
<a name="Borron.1"></a>Borron SW, Baud FJ. Intravenous 4-Methylpyrazole as an Antidote for Diethylene Glycol and Triethylene Glycol Poisoning: A Case Report. <i>Vet Hum Toxicol</i>. 1997;37(1):26-28.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11134452">
<a name="11134452"></a>Boyer EW, Mejia M, Woolf A, et al. Severe Ethylene Glycol Ingestion Treated Without Hemodialysis. <i>Pediatrics</i>. 2001;107(1):172-173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/11134452/pubmed" id="11134452" target="_blank">11134452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20586570">
<a name="20586570"></a>Brent J. Fomepizole for the treatment of pediatric ethylene and diethylene glycol, butoxyethanol, and methanol poisonings. <i>Clin Toxicol (Phila)</i>. 2010;48(5):401-406.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/20586570/pubmed" id="20586570" target="_blank">20586570</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Brent.1">
<a name="Brent.1"></a>Brent J, McMartin K, Phillips S, et al. 4-Methylpyrazole (Fomepizole) Therapy of Ethylene Glycol Poisoning: Preliminary Results of the Meta Trial. <i>J Toxicol Clin Toxicol</i>. 1997;35(5):507.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11172179">
<a name="11172179"></a>Brent J, McMartin K, Phillips S, et al. Fomepizole for the Treatment of Methanol Poisoning. <i>N Engl J Med</i>. 2001;344(6):424-429.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/11172179/pubmed" id="11172179" target="_blank">11172179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10080845">
<a name="10080845"></a>Brent J, McMartin K, Phillips S, et al; Methylpyrazole for Toxic Alcohols Study Group. Fomepizole for the treatment of ethylene glycol poisoning. <i>N Engl J Med</i>. 1999;340(11):832-838. doi:10.1056/NEJM199903183401102<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/10080845/pubmed" id="10080845" target="_blank">10080845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11581485">
<a name="11581485"></a>Brown MJ, Shannon MW, Woolf A, et al. Childhood Methanol Ingestion Treated With Fomepizole and Hemodialysis. <i>Pediatrics</i>. 2001;108(4):e77-e79.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/11581485/pubmed" id="11581485" target="_blank">11581485</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16871118">
<a name="16871118"></a>Calello DP, Osterhoudt KC, Henretig FM. New and novel antidotes in pediatrics. <i>Pediatr Emerg Care</i>. 2006;22(7):523-530. Erratum in intravenous n-acetylcysteine dosing [<i>Pediatr Emerg Care</i>. 2007].<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/16871118/pubmed" id="16871118" target="_blank">16871118</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11134450">
<a name="11134450"></a>Casavant MJ. Fomepizole in the treatment of poisoning. <i>Pediatrics</i>. 2001;107(1):170.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/11134450/pubmed" id="11134450" target="_blank">11134450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24332660">
<a name="24332660"></a>Chen TH, Kuo CH, Huang CT, Wang WL. Use of fomepizole in pediatric methanol exposure: the first case report in Taiwan and a literature review. <i>Pediatr Neonatol</i>. 2016;57(4):351-354<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/24332660/pubmed" id="24332660" target="_blank">24332660</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34336301">
<a name="34336301"></a>Chiu MH, Jaworska N, Li NL, Yarema M. Massive acetaminophen overdose treated successfully with N-acetylcysteine, fomepizole, and hemodialysis. <i>Case Rep Crit Care</i>. 2021;2021:6695967. doi:10.1155/2021/6695967<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/34336301/pubmed" id="34336301" target="_blank">34336301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10918103">
<a name="10918103"></a>Dart RC, Goldfrank LR, Chyka PA, et al. Combined evidence-based literature analysis and consensus guidelines for stocking of emergency antidotes in the United States. <i>Ann Emerg Med</i>. 2000;36(2):126-132.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/10918103/pubmed" id="10918103" target="_blank">10918103</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28669553">
<a name="28669553"></a>Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. <i>Ann Emerg Med</i>. 2018;71(3):314-325.e1. doi:10.1016/j.annemergmed.2017.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/28669553/pubmed" id="28669553" target="_blank">28669553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37552484">
<a name="37552484"></a>Dart RC, Mullins ME, Matoushek T, et al. Management of acetaminophen poisoning in the US and Canada: A consensus statement. <i>JAMA Netw Open</i>. 2023;6(8):e2327739. doi:10.1001/jamanetworkopen.2023.27739<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/37552484/pubmed" id="37552484" target="_blank">37552484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15578220">
<a name="15578220"></a>De Brabander N, Wojciechowski M, De Decker K, et al. Fomepizole as a Therapeutic Strategy in Paediatric Methanol Poisoning: A Case Report and Review of the Literature. <i>Eur J Pediatr</i>. 2005;164(3):158-161.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/15578220/pubmed" id="15578220" target="_blank">15578220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15329167">
<a name="15329167"></a>Detaille T, Wallemacq P, Clement de Clety S, et al. Fomepizole Alone for Severe Infant Ethylene Glycol Poisoning. <i>Pediatr Crit Care Med</i>. 2004;5(5):490-491.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/15329167/pubmed" id="15329167" target="_blank">15329167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11899949">
<a name="11899949"></a>Druteika DP, Zed PJ, Ensom MH. Role of Fomepizole in the Management of Ethylene Glycol Toxicity. <i>Pharmacotherapy</i>. 2002;22(3):365-372.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/11899949/pubmed" id="11899949" target="_blank">11899949</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fisher.1">
<a name="Fisher.1"></a>Fisher DM, Diaz JE. Pediatric Methanol Poisoning Treated With Fomepizole (Antizol®). <i>J Toxicol Clin Toxicol</i>. 1998;36:512.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22605809">
<a name="22605809"></a>Hann G, Duncan D, Sudhir G, West P, Sohi D. Antifreeze on a freezing morning: ethylene glycol poisoning in a 2-year-old. <i>BMJ Case Rep</i>. 2012;27:2012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/22605809/pubmed" id="22605809" target="_blank">22605809</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hung.1">
<a name="Hung.1"></a>Hung O, Kaplan J, Hoffman R, et al. Improved Understanding of the Ethanol-Chloral Hydrate Interaction Using 4-MP. <i>J Toxicol Clin Toxicol</i>. 1997;35(5):507-508.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8699551">
<a name="8699551"></a>Jacobsen D, McMartin KE. 4-Methylpyrazole - Present Status. <i>J Toxicol Clin Toxicol</i>. 1996;34(4):379-381.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/8699551/pubmed" id="8699551" target="_blank">8699551</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9120880">
<a name="9120880"></a>Jacobsen D, McMartin KE. Antidotes for Methanol and Ethylene Glycol Poisoning. <i>J Toxicol Clin Toxicol</i>. 1997;35(2):127-143.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/9120880/pubmed" id="9120880" target="_blank">9120880</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8793532">
<a name="8793532"></a>Jacobsen D, Ostensen J, Bredesen L, et al. 4-Methylpyrazole (4-MP) Is Effectively Removed by Haemodialysis in the Pig Model. <i>Hum Exp Toxicol</i>. 1996;15(6):494-496.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/8793532/pubmed" id="8793532" target="_blank">8793532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2212566">
<a name="2212566"></a>Jacobsen D, Sebastian CS, Barron SK, et al. Effects of 4-Methylpyrazole, Methanol/Ethylene Glycol Antidote in Healthy Humans. <i>J Emerg Med</i>. 1990;8(4):455-461.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/2212566/pubmed" id="2212566" target="_blank">2212566</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8699550">
<a name="8699550"></a>Jobard E, Harry P, Turcant A, et al. 4-Methylpyrazole and Hemodialysis in Ethylene Glycol Poisoning. <i>J Toxicol Clin Toxicol</i>. 1996;34(4):373-377.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/8699550/pubmed" id="8699550" target="_blank">8699550</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31768936">
<a name="31768936"></a>Kang AM, Padilla-Jones A, Fisher ES, et al. The effect of 4-methylpyrazole on oxidative metabolism of acetaminophen in human volunteers. <i>J Med Toxicol</i>. 2020;16(2):169-176. doi:10.1007/s13181-019-00740-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/31768936/pubmed" id="31768936" target="_blank">31768936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30956824">
<a name="30956824"></a>Kiernan EA, Fritzges JA, Henry KA, Katz KD. A case report of massive acetaminophen poisoning treated with a novel "triple therapy": N-acetylcysteine, 4-methylpyrazole, and hemodialysis. <i>Case Rep Emerg Med</i>. 2019;2019:9301432. doi:10.1155/2019/9301432<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/30956824/pubmed" id="30956824" target="_blank">30956824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29342392">
<a name="29342392"></a>Kraut JA, Mullins ME. Toxic alcohols. <i>N Engl J Med</i>. 2018;378(3):270-280. doi:10.1056/NEJMra1615295<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/29342392/pubmed" id="29342392" target="_blank">29342392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34585641">
<a name="34585641"></a>Lao YE, Vartdal T, Froeyshov S, et al. Fomepizole dosing during continuous renal replacement therapy - an observational study. <i>Clin Toxicol (Phila).</i> 2022;60(4):451-457. doi:10.1080/15563650.2021.1980581<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/34585641/pubmed" id="34585641" target="_blank">34585641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18639955">
<a name="18639955"></a>Lepik KJ, Levy AR, Sobolev BG, et al. Adverse drug events associated with the antidotes for methanol and ethylene glycol poisoning: a comparison of ethanol and fomepizole. <i>Ann Emerg Med</i>. 2009;53(4):439-450.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/18639955/pubmed" id="18639955" target="_blank">18639955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21740138">
<a name="21740138"></a>Lepik KJ, Sobolev BG, Levy AR, et al. Medication errors associated with the use of ethanol and fomepizole as antidotes for methanol and ethylene glycol poisoning. <i>Clin Toxicol (Phila)</i>. 2011;49(5):391-401.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/21740138/pubmed" id="21740138" target="_blank">21740138</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34709101">
<a name="34709101"></a>Link SL, Rampon G, Osmon S, Scalzo AJ, Rumack BH. Fomepizole as an adjunct in acetylcysteine treated acetaminophen overdose patients: a case series. <i>Clin Toxicol (Phila)</i>. 2022;60(4):472-477. doi:10.1080/15563650.2021.1996591<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/34709101/pubmed" id="34709101" target="_blank">34709101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26551875">
<a name="26551875"></a>McMartin K, Jacobsen D, Hovda KE. Antidotes for poisoning by alcohols that form toxic metabolites. <i>Br J Clin Pharmacol</i>. 2016;81(3):505-515. doi:10.1111/bcp.12824<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/26551875/pubmed" id="26551875" target="_blank">26551875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2911289">
<a name="2911289"></a>McMartin KE, Heath A. Treatment of Ethylene Glycol Poisoning With Intravenous 4-Methylpyrazole. <i>N Engl J Med</i>. 1989;320(2):125.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/2911289/pubmed" id="2911289" target="_blank">2911289</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22554311">
<a name="22554311"></a>McMartin KE, Sebastian CS, Dies D, Jacobsen D. Kinetics and metabolism of fomepizole in healthy humans. <i>Clin Toxicol</i>. 2012;50(5):375-383.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/22554311/pubmed" id="22554311" target="_blank">22554311</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12628894">
<a name="12628894"></a>Mokhlesi B, Leikin JB, Murray P, et al. Adult Toxicology in Critical Care: Part II: Specific Poisonings. <i>Chest.</i> 2003;123(3):897-922.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/12628894/pubmed" id="12628894" target="_blank">12628894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37681263">
<a name="37681263"></a>Pepin L, Matsler N, Fontes A, Heard K, Flaherty BF, Monte AA. Fomepizole therapy for acetaminophen-induced liver failure in an infant. <i>Pediatrics</i>. 2023;152(4):e2022061033. doi:10.1542/peds.2022-061033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/37681263/pubmed" id="37681263" target="_blank">37681263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34785186">
<a name="34785186"></a>Pourbagher-Shahri AM, Schimmel J, Shirazi FM, Nakhaee S, Mehrpour O. Use of fomepizole (4-methylpyrazole) for acetaminophen poisoning: a scoping review. <i>Toxicol Lett</i>. 2022;355:47-61. doi:10.1016/j.toxlet.2021.11.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/34785186/pubmed" id="34785186" target="_blank">34785186</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rampon.1">
<a name="Rampon.1"></a>Rampon G, Wartman H, Osmon S, Scalzo A. Use of fomepizole as an adjunct in the treatment of acetaminophen overdose: a case series. <i>Toxicology Communications</i>. 2020;4(1):1-4. https://www.tandfonline.com/loi/ttxc20. doi:10.1080/24734306.2019.1705596</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25493973">
<a name="25493973"></a>Roberts DM, Yates C, Megarbane B, et al. Recommendations for the role of extracorporeal treatments in the management of acute methanol poisoning: a systematic review and consensus statement. <i>Crit Care Med</i>. 2015;43(2):461-472.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/25493973/pubmed" id="25493973" target="_blank">25493973</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31785979">
<a name="31785979"></a>Shah KR, Beuhler MC. Fomepizole as an adjunctive treatment in severe acetaminophen toxicity. <i>Am J Emerg Med</i>. 2020;38(2):410.e5-410.e6. doi:10.1016/j.ajem.2019.09.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/31785979/pubmed" id="31785979" target="_blank">31785979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32538692">
<a name="32538692"></a>Shah KR, Fox C, Geib AJ, et al. Fomepizole as an adjunctive treatment in severe acetaminophen ingestions: a case series. <i>Clin Toxicol (Phila)</i>. 2021;59(1):71-72. doi:10.1080/15563650.2020.1775847<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/32538692/pubmed" id="32538692" target="_blank">32538692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26594941">
<a name="26594941"></a>Thanacoody RH, Gilfillan C, Bradberry SM, et al. Management of poisoning with ethylene glycol and methanol in the UK: a prospective study conducted by the National Poisons Information Service (NPIS). <i>Clin Toxicol (Phila)</i>. 2016;54(2):134-140.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/26594941/pubmed" id="26594941" target="_blank">26594941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23008459">
<a name="23008459"></a>Wang GS, Yin S, Shear B, Heard K. Severe poisoning after accidental pediatric ingestion of glycol ethers. <i>Pediatrics</i>. 2012;130(4):e1026-1029.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/23008459/pubmed" id="23008459" target="_blank">23008459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17110870">
<a name="17110870"></a>White ML, Liebelt EL. Update on antidotes for pediatric poisoning. <i>Pediatr Emerg Care</i>. 2006;22(11):740-746.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/17110870/pubmed" id="17110870" target="_blank">17110870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31785980">
<a name="31785980"></a>Woolum JA, Hays WB, Patel KH. Use of fomepizole, n-acetylcysteine, and hemodialysis for massive acetaminophen overdose. <i>Am J Emerg Med</i>. 2020;38(3):692.e5-692.e7. doi:10.1016/j.ajem.2019.09.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/31785980/pubmed" id="31785980" target="_blank">31785980</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26109326">
<a name="26109326"></a>Zakharov S, Pelclova D, Navratil T, et al. Fomepizole versus ethanol in the treatment of acute methanol poisoning: Comparison of clinical effectiveness in a mass poisoning outbreak. <i>Clin Toxicol (Phila)</i>. 2015;53(8):797-806.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fomepizole-pediatric-drug-information/abstract-text/26109326/pubmed" id="26109326" target="_blank">26109326</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13323 Version 143.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
